Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma

doi:10.3748/wjg.v20.i1.264

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 1

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6335)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

269

WORD

198

HTML

2954

Figures (1-2)

192

Tables (1-3)

164

Sum=3777

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1366

Download

1192

Sum=2558

Jan 7, 2014 (publication date) through Nov 18, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Jan 7, 2014; 20(1): 264-273
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.264

Open in New Tab Full Size Figure Download Figure

Figure 1 Kaplan-Meier curves for overall survival of patients after D2 gastrectomy for stage II/III gastric adenocarcinoma. A: Adjuvant chemotherapy or not in the entire cohort; B: Adjuvant chemotherapy or not in stage IIIB/IIIC patients; C: p53 tumor status as measured by immunohistochemistry; D: CEA tumor status as measured by immunohistochemistry. HR and 95%CI were calculated with green curves as references. CEA: Carcinoembryonic antigen.

Open in New Tab Full Size Figure Download Figure

Figure 2 Kaplan-Meier curves for disease-free survival of patients after D2 gastrectomy for stage II/III gastric adenocarcinoma. A: Adjuvant chemotherapy or not in the entire cohort; B: Adjuvant chemotherapy or not in stage IIIB/IIIC patients; C: p53 tumor status as measured by immunohistochemistry; D: CEA tumor status as measured by immunohistochemistry. HR and 95%CI were calculated with green curves as references. CEA: Carcinoembryonic antigen.

Citation: He MM, Zhang DS, Wang F, Wang ZQ, Luo HY, Ren C, Jin Y, Chen DL, Xu RH. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma. World J Gastroenterol 2014; 20(1): 264-273
URL: https://www.wjgnet.com/1007-9327/full/v20/i1/264.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i1.264